MedTrace Logo

Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers

NCT03596632 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-12-06

No results posted yet for this study

Summary

The purpose of this study is to determine the excretion kinetics and mass balance of fenebrutinib in healthy male subjects.

Conditions

  • Healthy Participants

Interventions

DRUG

Fenebrutinib

200-mg (100 µCi) oral solution 14C/12C\]-fenebrutinib

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-27
Primary Completion
2018-08-23
Completion
2018-08-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03596632 on ClinicalTrials.gov